Lineage Cell Therapeutics (LCTX) stock
LCTX's Quality Score rose 1 point on Mon, Oct 5, to -2. Made a higher high and a higher low.
Follow LCTX's trial news. Pro members can get an alert when Lineage Cell Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
What's next for LCTX, and how long its cash lasts
From Lineage Cell Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
About 8 quarters
Dilution on the horizon
- Shelf registration (S-3, filed Mar 11, 2026)
- At-the-market share sales program (S-3, filed Mar 11, 2026)
Insiders
CEO Brian M Culley bought 15,000 shares on Mar 12.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 24 daysINOInovio Pharmaceuticals
INOINO-3107
- In 35 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 47 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why it's down
Down 30% in 3 months, 12% under its 50-day average.
Down more than its industry: the 299 other stocks in it fell a median 14% over the same 3 months.
−2Long-term trend below a falling 200-day average, down over one year
3 more things pulling LCTX's score down, for Pro members
What's next
Expected to report Thu Nov 5, after the close
After its last 4 reports it closed -1.0% on average, higher 2 of 4 times.
What would turn LCTX's score around: 8 things, for Pro members
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
LCTX has 1 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1438.8
- MACD (12, 26, 9)Below signal
- 50-day average$1.06
- 200-day average$1.39
- ADX 1413.8
- Resistance$1.12
- Bollinger Bands (20, 2)Inside
- Volume0.9x
How LCTX ranks in Biotech
LCTX is #189 of 300 by Quality Score. The top three are shown with their scores, and more by name.
ONC8/1420
RGEN8/1420
CORT8/1418
KURAOpen for its score
KYMROpen for its score
LENZOpen for its score
LFCROpen for its score
LCTX1/14-2
When does LCTX report earnings, and what happens after?
Expected to report Thu Nov 5, after the close (in 30 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 6, 2026After close | After close | -2.6% | -2.6% | -6.2% |
| May 12, 2026After close | After close | +0.8% | -3.8% | -9.8% |
| Mar 5, 2026After close | After close | +5.4% | +0.5% | -14.1% |
| Nov 6, 2025After close | After close | -9.3% | +1.7% | +4.0% |
About Lineage Cell Therapeutics
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
Pro members see every line of every stock's score.
- Real-time prices, no delay
- Every line of LCTX's score, with the points and the reason
- All 14 checks on LCTX and on all 3,243 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on LCTX
Straight Answers
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.